替吉奥胶囊对食管癌适形放疗增敏作用的临床观察  

Clinical Observation about the effect of S-1 on radio-sensitivity in conformal radio therapy of esophageal cancer

作　　者：孙瑶[1] 冯保同[2] 张士义[1] 付永兴[1] 王莹[2] 

机构地区：[1]潍坊医学院附属益都中心医院放疗科,山东潍坊262500 [2]潍坊医学院附属益都中心医院血液科,山东潍坊262500

出　　处：《中华肿瘤防治杂志》2012年第18期1410-1412,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:观察替吉奥胶囊(S-1)对食管癌适形放疗的增敏作用。方法:2009-07-01-2010-11-30采用随机分组对83例食管癌进行适形放射治疗,其中42例放射治疗同时口服S-1(治疗组),41例行单纯适形放疗(对照组)。结果:治疗组同对照组相比较其有效率、1年生存率、鳞状上皮细胞抗原(SCC)水平降低率分别为88.1%、70.7%(χ2=3.841,P<0.05),78.6%、58.5%(χ2=3.871,P<0.05),60.0%、25.0%(χ2=7.789,P<0.05),差异均有统计学意义;治疗组同对照组相比较其Ⅰ～Ⅱ度骨髓抑制率、肝肾能损害率、放射性食管炎发生率分别为28.6%、19.5%,14.2%、4.8%,66.7%、56.1%,差异均无统计学意义(P>0.05)。结论:S-1可以提高食管癌适形放疗的有效率及1年生存率,降低患者SCC水平且无明显增加放疗的毒副作用。OBJECTIVE：To observe the effect of S-1 on radio-sensitivity in conformal radio therapy of esophageal cancer. METHODS： From July 2009 to November 2010,S-1 were used as radio-sensitizer combined with radiation to treat esophageal cancer. A total of 83 patients were randomized into two groups,42 patients were treated by conformal radio- therapy combined with S-1 （treatment group）, and 41 patients were rated by eonformal radiotherapy alone （control group）. RESULTS： The 1-year survival rate and lower rate for squamous cell carcinoma antigen （SCC） level in treatment group and control group were 88.1% and 70.7%（X2=3.841,P〈0.05）,78.6% and 58.5% （X2 =3. 871,P〈0. 05）, 60.0% and 25.0% （X2 =7. 789,P〈0.05）. The rate of I - Ⅱ degree bone marrow inhibition,hepatic and renal impair- ment and the incidence of radiation-induced esophagitis in treatment group and control group were 28.6% and 19.5%, 14.2 % and 4.8 %, 66.7 % and 56.1 % （P〉0.05）. CONCLUSION： For esophageal carcinoma S-1 can improve the efficien- cy of conformai radiotherapy and the patients＇ 1-year survival rate, reduce the SCC levels in patients without a significant increase in side effects of radiotherapy.

关 键 词：食管肿瘤 适形放疗 替吉奥 放疗增敏 

分 类 号：R735.1[医药卫生—肿瘤]